Table 1

ROP in neonates of 240–276 weeks' gestation in iNeo participants between 2007 and 2013

NetworkANZNNCNNINNNRNJSNQSwissNeo NetSEN1500UKNC*FinMBRTuscanNNTotal
Study infants (240–276 weeks), n71147019288910 24417451421544010 99684737248 087
Surviving to 32 weeks PMA (%)5969 (83.9)5806 (82.7)1998 (69.2)9360 (91.8)1506 (86.3)1129 (79.5)3686 (67.8)8920 (81.2)712 (86.7)270 (72.6)39 356 (81.8)
Screened for ROP (% of survivors)5773 (96.7)5142 (88.6)1989 (99.6)9019 (96.4)1474 (97.9)1107 (98.1)3425 (92.9)8792 (98.5)664 (91.1)268 (99.3)37 653 (95.0)
GA† (weeks %)
 2413.112.68.318.113.49.68.514.514.817.913.9
 2521.824.519.122.322.118.819.320.120.920.921.4
 2630.429.132.827.629.234.231.729.026.121.629.4
 2734.733.839.932.035.437.440.536.438.339.635.3
Birth weight†<1000 g (%)4229 (73.3)3832 (74.5)1490 (74.9)7541 (83.6)1095 (74.3)880 (79.5)2471 (72.2)6569 (74.7)485 (73.0)204 (76.1)28 796 (76.5)
Retinopathy treatment, n (% of screened)424 (7.3)537 (10.4)210 (10.7)2740 (30.4)157 (10.7)47 (4.3)456 (13.3)743 (8.5)78 (11.8)27 (10.1)5419 (24.9)
Death or ROP treatment (% of study infants)1569 (22.1)1750 (24.9)1101 (38.1)3582 (35.0)396 (22.7)339 (23.9)2210 (40.6)2819 (25.6)213 (25.2)129 (34.7)14 108 (29.3)
  • *UKNC excluded infants who died <37 weeks PMA.

  • †Among infants surviving to 32 weeks PMA.

  • ANZNN, Australia and New Zealand Neonatal Network; CNN, Canadian Neonatal Network; FinMBR, Finnish Maternal Birth Register; GA, gestational age; iNeo, International Network for Evaluating Outcomes; INN, Israel Neonatal Network; NRNJ, Neonatal Research Network of Japan; PMA, postmenstrual age; ROP, retinopathy of prematurity; SEN1500, Spanish Neonatal Network; SNQ, Swedish Neonatal Quality Register; SwissNeoNet, Swiss Neonatal Network; TuscanNN, Tuscan Neonatal Network; UKNC, UK Neonatal Collaborative.